reports
- Wedbush Research
TSLA TESLA INC
NVDA NVIDIA CORPORATION
GOOGL ALPHABET INC. CLASS A
ROKU ROKU INC. CLASS A
MSFT MICROSOFT CORPORATION
DNLI DENALI THERAPEUTICS INC
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
PLTR PALANTIR TECHNOLOGIES
VERA VERA THERAPEUTICS INC
PL PLANET LABS PBC
TYRA TYRA BIOSCIENCES INC
CGON CG ONCOLOGY INC
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- Laura Chico
- Thomas Yip
Vera Therapeutics Announces Pricing of Public Offering of Class A Comm...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at a price to the public of $42.50 per share. The gross proceeds to Vera Therapeutics from the offering, before deducting underwriting discounts ...
Vera Therapeutics Announces Proposed Public Offering of Class A Common...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its Class A common stock. All of the shares are being offered by Vera Therapeutics. In connection with the proposed...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rul...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 42,000 shares of Class A common stock and restricted stock units (RSUs) underlying 21,000 shares of Class A common stock to seven (7) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). Th...
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers t...
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics’ Board of Directors. "We are thrilled to welcome Jim to our Board of...
Erasca to Present at the 8th Annual Evercore Healthcare Conference
Erasca to Present at the 8th Annual Evercore Healthcare Conference SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 8th Annual Evercore Healthcare Conference being held at the Loews Coral Gables Hotel in Coral Gables, FL. Management will participate in a fireside chat on Wednesday, December 3, 2025, at 10:25 am Eastern Time and will also participate in on...
Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: 8th Annual Evercore Healthcare ConferenceFormat: Fireside Chat and 1x1sWebcast: Date: Tuesday, Decembe...
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
RGP RESOURCES CONNECTION INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FLDM FLUIDIGM
FDS FACTSET RESEARCH SYSTEMS INC.
AROW ARROW FINANCIAL CORP.
GAM GENERAL AMERICAN INVESTORS CO. INC.
WHF WHITEFIELD
FMC FMC CORPORATION
LPX LOUISIANA-PACIFIC CORPORATION
SXC SUNCOKE ENERGY INC.
ITGR INTEGER HOLDINGS CORPORATION
ICHR ICHOR HOLDINGS LTD.
KREF KKR REAL ESTATE FINANCE TRUST
NWPP NEW PEOPLES BANKSHARES INC.
REZI RESIDEO TECHNOLOGIES
WU INC.
AEYE THE WESTERN UNION COMPANY
AMCR AUDIOEYE INC
BW AMCOR PLC
THRY BABCOCK & WILCOX ENTERPRISES
UTZ THRYV HOLDINGS
OPEN UTZ BRANDS INC (A)
ACVA OPENDOOR TECHNOLOGIES INC.
UPST ACV AUCTIONS INC.
FRSH UPSTART HOLDINGS
CLVT FRESHWORKS INC.
TRDA CLARIVATE PLC
SG ENTRADA THERAPEUTICS INC
TBBK SWEETGREEN INC
BLND THE BANCORP
CRVO INC.
NEXT ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
SPRU CERVOMED INC
LAW NEXTSOURCE MATERIALS INC.
MRAI SPRUCE POWER HOLDING CORP
BNTC CS DISCO INC
GF MARPAI
HYMC INC.
SENS BENITEC BIOPHARMA INC
BATRK THE NEW GERMANY FUND
INC.
HYCROFT MINING HOLDING CORPORATION
SENSEONICS HOLDINGS INC.
LIBERTY MEDIA CORP
- Jonathan Moreland
RGP RESOURCES CONNECTION INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FAST FASTENAL COMPANY
TZOO TRAVELZOO
ITGR INTEGER HOLDINGS CORPORATION
BX THE BLACKSTONE GROUP L.P.
REZI RESIDEO TECHNOLOGIES
AEYE INC.
BW AUDIOEYE INC
PNTG BABCOCK & WILCOX ENTERPRISES
MRVI PENNANT GROUP
UPST MARAVAI LIFESCIENCES HOLDINGS
NEXT UPSTART HOLDINGS
CLVT NEXT CAPITAL
OGN CLARIVATE PLC
MYPS ORGANON & CO
FRST PLAYSTUDIOS INC
RBA PRIMIS FINANCIAL CORP
CRVO RITCHIE BROS AUCTIONEERS INC.
GAM CERVOMED INC
MDRR GENERAL DE ALQUILER DE MAQUINARIA
SENS MEDALIST DIVERSIFIED REIT INC.
BATRK SENSEONICS HOLDINGS INC.
LIBERTY MEDIA CORP
Erasca Reports Third Quarter 2025 Business Updates and Financial Resul...
Erasca Reports Third Quarter 2025 Business Updates and Financial Results U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015 Strengthened scientific leadership with promotion of Robert Shoemaker, Ph.D., to chief scientific officer Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $362 million as of September 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Nov. 12,...
- Wedbush Research
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
TVTX INC.
RZLT TRAVERE THERAPEUTICS INC
STX REZOLUTE
VERA SEAGATE TECHNOLOGY HLDGS PLC
GFS VERA THERAPEUTICS INC
ALCC GLOBALFOUNDRIES INC
DBD ALTC ACQUISITION CORP
MAZE DIEBOLD NIXDORF INCORPORATED
JBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
- Laura Chico
- Thomas Yip
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
35G GENPACT LIMITED
EXPE EXPEDIA GROUP INC.
CRK COMSTOCK RESOURCES INC.
AXTI AXT INC.
ALB ALBEMARLE CORPORATION
ACRE ARES COMMERCIAL REAL ESTATE
AGO ASSURED GUARANTY LTD.
HRTG HERITAGE INSURANCE HOLDINGS INC.
DRH DIAMONDROCK HOSPITALITY COMPANY
ELY CALLAWAY GOLF COMPANY
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
TALO TALOS ENERGY INC.
LASR NLIGHT
GLOB GAZIT-GLOBE LTD.
ARVN ARVINAS HOLDING
PLMR PALOMAR HOLDINGS
BW BABCOCK & WILCOX ENTERPRISES
TXG 10X GENOMICS INC CLASS A
PGNY PROGYNY
AMPY AMPLIFY ENERGY
EOSE EOS ENERGY ENTERPRISES INC (A)
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
DOCN DIGITALOCEAN HLDGS INC
DSGN DESIGN THERAPEUTICS INC
FIGS FIGS INC
YOU ONTO INNOVATION INC.
PPTA CLEAR SECURE INC
AMPX PERPETUA RESOURCES CORP
OS AMPRIUS TECHNOLOGIES INC
SNDK ONESTREAM INC
CSIOX SANDISK CORP
BALY CATALYST PERINI STRATEGIC INCOM ORD
HOII BALLY'S CORPORATION
REX HOOD GROWTH & INCOME ETF
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflamma...
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12-13, 2025. The management team will also participate in one-on-one investor meetings. Presentati...
Vera Therapeutics Submits Biologics License Application to U.S. FDA th...
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 (p
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rul...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 79,050 shares of Class A common stock and restricted stock units (RSUs) underlying 39,915 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
LGND LIGAND PHARMACEUTICALS INCORPORATED
PLNT PLANET FITNESS INC. CLASS A
HOO HERBALIFE NUTRITION LTD.
COLL COLLEGIUM PHARMACEUTICAL INC.
AMBA AMBARELLA INC.
SKY SKYLINE CHAMPION CORPORATION
NYT NEW YORK TIMES COMPANY CLASS A
DLX DELIGNIT AG
MTSI MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC.
NOMDN NOMAD FOODS LTD.
LILA LIBERTY LATIN AMERICA A
DUBA DRDGOLD LTD. ADS
BW BABCOCK & WILCOX ENTERPRISES
SITM SITIME
LZ LEGALZOOM.COM INC
DERM JOURNEY MEDICAL CORP
COHR COHERENT CORP
GPCR STRUCTURE THERAPEUTICS
SBGI SINCLAIR INC
FBYD FALCONS BEYOND GLOBAL INC
MRX MAREX GROUP PLC
LB LANDBRIDGE COMPANY LLC
ORKA ORUKA THERAPEUTICS INC
ECG_w EVERUS CONSTRUCTION GROUP INC.
BKTI BK TECHNOLOGIES CORP
RAL RALLIANT CORP
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept...
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular ...
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043 Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Patent and Tra...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.